Hybrigenics: the title rises after a point on B Cell Design


(CercleFinance.com) – Hybrigenics rose sharply on the Paris Stock Exchange on Wednesday after taking stock of its subsidiary B Cell Design, which specializes in the development of artificial antibodies.

In a press release, the biopharmaceutical company specifies that this entity, acquired in 2021, is already generating revenue and that it will grow rapidly to represent a “strategic asset” for the company.

B Cell Design develops artificial immunoglobulins intended for scientific research, but also for the diagnostic industry.

According to Hybrigenics, this market represents a total amount of around 100 billion dollars, with rapid annual growth of around 20% over the last few years.

The company explains that research and the diagnostics industry are in constant demand for artificial antibodies, capable of reproducing human antibodies, in order to develop drugs and to replace human serum in diagnostic kits.

The originality of B Cell Design’s approach lies in its ability to produce human chimeric antibodies directly in animals, which gives it a technological lead over its competitors.

Currently, its antibodies are marketed through an international network of distributors, including the companies Virion in Germany, BBI and Surmodics in the United States and Shanghai BioSun in Asia.

Following these announcements, Hybrigenics shares climbed more than 14% on Wednesday on the Paris Stock Exchange, giving it a market capitalization of 19.4 million euros.

Copyright © 2023 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.


Twitter


Facebook


LinkedIn


E-mail





Source link -85